Neuronetics, INC DEF 14A proxy statements

Neuronetics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, executive compensation, and an equity incentive plan.

Neuronetics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Neuronetics, Inc. is holding its annual virtual stockholder meeting on May 22, 2025, to vote on key proposals including director elections, auditor ratification, executive compensation, and amendments to corporate governance documents.

Neuronetics, Inc. amended its Registration Rights Agreement with the Madryn Parties, extending the Demand Registration Period from 180 to 365 days following the consummation of the Arrangement.

Neuronetics, Inc. has engaged D.F. King & Co., Inc. to assist in soliciting proxies for its Special Meeting of Stockholders to be held on November 8, 2024.

Neuronetics and Greenbrook TMS have received an interim order from the Ontario Superior Court of Justice for their proposed all-stock transaction, with shareholder meetings scheduled for November 8, 2024.

Neuronetics and Greenbrook TMS have entered into an arrangement agreement for Neuronetics to acquire all outstanding common shares of Greenbrook in an all-stock transaction.

Neuronetics, Inc. will acquire Greenbrook TMS Inc. in an all-stock transaction, combining two major mental health companies to expand treatment access and achieve cost synergies.

Neuronetics is set to acquire Greenbrook TMS to leverage combined strengths, amplify brand awareness, and provide enhanced value to NeuroStar practices.

Neuronetics and Greenbrook TMS are merging to form a larger, vertically integrated organization focused on providing comprehensive mental health treatment.

Neuronetics will acquire Greenbrook TMS in a stock-for-stock transaction, aiming to create a leading player in the mental health treatment sector.

Neuronetics announces the acquisition of Greenbrook TMS, aiming to create a vertically integrated leader in mental health therapies.

Neuronetics announces a definitive agreement to acquire Greenbrook TMS in an all-stock transaction, aiming to create a leading mental health provider, while also reporting a 7% decrease in Q2 2024 revenue.

Neuronetics, Inc. has filed a definitive proxy statement with the SEC, soliciting material pursuant to Section 240.14a-12.

Neuronetics, Inc. announces its annual stockholder meeting to be held virtually on May 30, 2024, featuring proposals for director elections, auditor ratification, and executive compensation advisory votes.